ICCC vs. ELDN, ESPR, TVGN, SOPH, SLRN, DSGN, UPXI, MDWD, BTMD, and LRMR
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), Semper Paratus Acquisition (TVGN), SOPHiA GENETICS (SOPH), Acelyrin (SLRN), Design Therapeutics (DSGN), Upexi (UPXI), MediWound (MDWD), biote (BTMD), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.
ImmuCell vs. Its Competitors
ImmuCell (NASDAQ:ICCC) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 6.6% of ImmuCell shares are held by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 1 mentions for ImmuCell. Eledon Pharmaceuticals' average media sentiment score of 0.96 beat ImmuCell's score of 0.67 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.
Eledon Pharmaceuticals has a net margin of 0.00% compared to ImmuCell's net margin of -1.00%. ImmuCell's return on equity of -1.02% beat Eledon Pharmaceuticals' return on equity.
ImmuCell has higher revenue and earnings than Eledon Pharmaceuticals. ImmuCell is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eledon Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 143.24%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than ImmuCell.
ImmuCell has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500.
Summary
Eledon Pharmaceuticals beats ImmuCell on 9 of the 15 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
This page (NASDAQ:ICCC) was last updated on 7/21/2025 by MarketBeat.com Staff
